Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.
Rgenta Therapeutics has raised $8.0M in total funding. The most recent round was Series A. The last funding was announced in May 2023.
Rgenta Therapeutics's investors include AstraZeneca, Vivo Capital, Highlight Capital, Matrix Partners China, Lilly Asia Ventures.
Rgenta Therapeutics is headquartered in Cambridge, United States.
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.
Rgenta Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rgenta Therapeutics — Funding & Investors." VCBacked, May 8, 2023, https://www.vcbacked.co/company/rgenta-therapeutics. Accessed July 19, 2026.
VCBacked. (2023). Rgenta Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/rgenta-therapeutics
{{cite web |title=Rgenta Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/rgenta-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated